Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19628965 | 0.83 | AR (0.41) | ARTSHRALDH1A1 | |
| SCHEMBL10944659 | 0.82 | AR (0.43) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL9715679 | 0.80 | AR (0.46) | ARTSHRALDH1A1HTR2AHTR2C | |
| SCHEMBL410450 | 0.80 | TSHR (0.44) | ARTSHRALDH1A1 | |
| SCHEMBL12957943 | 0.78 | TSHR (0.43) | ARTSHRALDH1A1 | |
| SCHEMBL8664256 | 0.78 | TRPV4 (0.42) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL31542127 | 0.78 | TRPV4 (0.42) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL3333071 | 0.78 | CYP11B2 (0.42) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL29863815 | 0.78 | AR (0.51) | ARTSHRALDH1A1 | |
| SCHEMBL13106347 | 0.78 | AR (0.51) | ARTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3793994-B1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| WO-2020232330-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-9809583-B2 | Oxazolidine-based compound and selective androgen receptor agonist comprising same | DONG-A ST CO., LTD. (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170050955-A1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | DONG-A ST CO., LTD. (KR) | 2017-02-23 | — | — | US | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | AR 1/4885TSHR 1988/4885ALDH1A1 460/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | AR 1/4885TSHR 1662/4885ALDH1A1 798/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | AR 1/4885TSHR 1689/4885ALDH1A1 824/4885 |
| US-20170050955-A1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | AR, SHBG, MUSK | AR 1/4885TSHR 401/4885ALDH1A1 1632/4885 |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | AR 3776/4885TSHR 3772/4885ALDH1A1 3671/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | AR 1/4885TSHR 408/4885ALDH1A1 1002/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | AR 3776/4885TSHR 3772/4885ALDH1A1 3671/4885 |
| US-20160045607-A1 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE | GPER1, PSMA3, ESR2 | AR 88/4885TSHR 1265/4885ALDH1A1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.